These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32135514)

  • 1. Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma.
    Ghatalia P; Plimack ER
    J Natl Compr Canc Netw; 2020 Mar; 18(3):355-361. PubMed ID: 32135514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of systemic immunotherapy for advanced urothelial carcinoma.
    Gartrell BA; He T; Sharma J; Sonpavde G
    Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of immunotherapy in urological cancers.
    Bosnali E; Akdas EM; Telli E; Teke K; Kara O
    Arch Ital Urol Androl; 2024 May; 96(2):12307. PubMed ID: 38818794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [First-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zacharis A; Grüllich C
    Urologe A; 2020 Jul; 59(7):797-803. PubMed ID: 32500171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
    Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
    Koshkin VS; Grivas P
    Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.
    Hussain SA; Birtle A; Crabb S; Huddart R; Small D; Summerhayes M; Jones R; Protheroe A
    Eur Urol Oncol; 2018 Dec; 1(6):486-500. PubMed ID: 31158093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on immunotherapy options for urothelial cancer.
    Bilgin B; Sendur MAN; Hizal M; Yalçın B
    Expert Opin Biol Ther; 2019 Dec; 19(12):1265-1274. PubMed ID: 31518156
    [No Abstract]   [Full Text] [Related]  

  • 9. A Review of Immune Checkpoint Inhibitors for the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
    Hanna KS
    Pharmacotherapy; 2017 Nov; 37(11):1391-1405. PubMed ID: 28950037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice.
    Nabar ND; Brandt MP; Thomas C; Tsaur I; Bartsch G; Jaeger W; Haferkamp A; Höfner T
    Minerva Urol Nefrol; 2019 Jun; 71(3):205-216. PubMed ID: 30021426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immune checkpoint inhibition in metastatic urothelial carcinoma].
    Bedke J; Todenhöfer T; Stenzl A
    Aktuelle Urol; 2018 Apr; 49(2):178-186. PubMed ID: 29587323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibition in upper tract urothelial carcinoma.
    Califano G; Ouzaid I; Verze P; Hermieu JF; Mirone V; Xylinas E
    World J Urol; 2021 May; 39(5):1357-1367. PubMed ID: 33128595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
    Ghatalia P; Zibelman M; Geynisman DM; Plimack E
    Ther Adv Med Oncol; 2018; 10():1758835918788310. PubMed ID: 30083254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy and urothelial carcinoma: An overview and future prospectives.
    Pierantoni F; Maruzzo M; Gardi M; Bezzon E; Gardiman MP; Porreca A; Basso U; Zagonel V
    Crit Rev Oncol Hematol; 2019 Nov; 143():46-55. PubMed ID: 31476551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
    Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
    Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
    Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
    Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Second-line treatment of metastatic urothelial carcinoma : Update immuno-oncology].
    Zschäbitz S; Niegisch G
    Urologe A; 2020 Jul; 59(7):804-809. PubMed ID: 32472222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of immunotherapy targeting the PD-1 pathway for advanced urothelial carcinoma: a meta-analysis of published clinical trials.
    Zhang F; Liu Z; Liang J; Zhang F; Wu K; Zhou C; Lu Y; Wang X
    Clin Transl Oncol; 2020 Oct; 22(10):1750-1761. PubMed ID: 32086783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durvalumab for the treatment of urothelial carcinoma.
    Alsharedi M; Srivastava R; Elmsherghi N
    Drugs Today (Barc); 2017 Dec; 53(12):647-652. PubMed ID: 29517083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma.
    Tsimafeyeu I; Tjulandin S
    BJU Int; 2019 Apr; 123(4):563-565. PubMed ID: 30457694
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.